Wilschut J - Search Results

1

Influenza vaccines: the virosome concept.

Wilschut J. Wilschut J. Immunol Lett. 2009 Feb 21;122(2):118-21. doi: 10.1016/j.imlet.2008.11.006. Epub 2008 Dec 25. Immunol Lett. 2009. PMID: 19100779 Review.

2

The virosome concept for influenza vaccines.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. Huckriede A, et al. Among authors: wilschut j. Vaccine. 2005 Jul 8;23 Suppl 1:S26-38. doi: 10.1016/j.vaccine.2005.04.026. Vaccine. 2005. PMID: 16026906 Review.

3

Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides.

Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Heikema A, et al. Among authors: wilschut j. Immunol Lett. 1997 Jun 1;57(1-3):69-74. doi: 10.1016/s0165-2478(97)00048-5. Immunol Lett. 1997. PMID: 9232428

4

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Bungener L, et al. Among authors: wilschut j. Vaccine. 2005 Jan 26;23(10):1232-41. doi: 10.1016/j.vaccine.2004.09.002. Vaccine. 2005. PMID: 15652665

5

Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Liu H, de Vries-Idema J, Ter Veer W, Wilschut J, Huckriede A. Liu H, et al. Among authors: wilschut j. Med Microbiol Immunol. 2014 Feb;203(1):47-55. doi: 10.1007/s00430-013-0313-2. Epub 2013 Sep 24. Med Microbiol Immunol. 2014. PMID: 24062182

6

Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages.

de Haan A, Groen G, Prop J, van Rooijen N, Wilschut J. de Haan A, et al. Among authors: wilschut j. Immunology. 1996 Dec;89(4):488-93. doi: 10.1046/j.1365-2567.1996.d01-787.x. Immunology. 1996. PMID: 9014811 Free PMC article.

7

The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity.

de Mare A, Bungener LB, Regts J, de Vries-Idema J, van der Zee AG, Wilschut J, Daemen T. de Mare A, et al. Among authors: wilschut j. Vaccine. 2008 May 2;26(19):2314-21. doi: 10.1016/j.vaccine.2008.03.002. Epub 2008 Mar 19. Vaccine. 2008. PMID: 18400343

8

Influenza virosomes in vaccine development.

Huckriede A, Bungener L, Daemen T, Wilschut J. Huckriede A, et al. Among authors: wilschut j. Methods Enzymol. 2003;373:74-91. doi: 10.1016/S0076-6879(03)73005-5. Methods Enzymol. 2003. PMID: 14714397

9

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A. de Vries JJ, et al. Among authors: wilschut j. Vaccine. 2009 Feb 5;27(6):947-55. doi: 10.1016/j.vaccine.2008.11.046. Epub 2008 Dec 4. Vaccine. 2009. PMID: 19059296

10

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. Geeraedts F, et al. Among authors: wilschut j. PLoS Pathog. 2008 Aug 29;4(8):e1000138. doi: 10.1371/journal.ppat.1000138. PLoS Pathog. 2008. PMID: 18769719 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

358 results

Search Page